Intellia Therapeutics (NTLA) Shares Outstanding (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Shares Outstanding data on file, last reported at $120.4 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $120.4 million, up 16.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.4 million (up 16.33% YoY), and the FY2025 annual result was $116.3 million, up 14.0% from the prior year.
• Shares Outstanding climbed to $120.4 million in Q1 2026 per NTLA's latest filing, from $116.3 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $120.4 million in Q1 2026 and troughed at $24316.0 in Q3 2022.
• A 5-year average of $80.2 million and a median of $89.1 million in 2023 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding surged 366316.44% in 2023, then sank 99.9% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $87.1 million in 2022, then advanced by 6.77% to $93.0 million in 2023, then advanced by 9.71% to $102.0 million in 2024, then grew by 14.0% to $116.3 million in 2025, then climbed by 3.55% to $120.4 million in 2026.
• Business Quant data shows NTLA's Shares Outstanding at $120.4 million in Q1 2026, $116.3 million in Q4 2025, and $115.8 million in Q3 2025.